{{Infobox company
| name             = Compugen Ltd.
| logo             = [[File:Compugen logo.gif]]
| caption          =
| type             = [[Public company|Public]]
| traded_as        = {{NASDAQ|CGEN}}<br />{{TASE|CGEN}}
| fate             =
| predecessor      =
| successor        =
| foundation       = {{Start date|1993}}
| founder          = Eli Mintz<br />Simchon Faigler<br />Amir Natan
| defunct          = <!-- {{End date|YYYY|MM|DD}} -->
| location_city    = [[Tel Aviv]]
| location_country = [[Israel]]
| location         =
| locations        =
| area_served      =
| key_people       = [[Martin Gerstel]] <small>(Chairman)</small><br />[[Anat Cohen-Dayag]] <small>(Pres. & CEO)</small>
| industry         = [[Biotechnology]]
| products         =
| services         =
| revenue          = {{Increase}} [[United States dollar|US$]] 1.1 million <small>''(2010)''</small>
| operating_income = {{Steady}} US$ -7.9 million <small>''(2010)''</small>
| net_income       = {{Decrease}} US$ -7.2 million <small>''(2010)''</small>
| assets           =
| equity           =
| owner            =
| num_employees    =
| parent           =
| divisions        =
| subsid           =
| homepage         = {{URL|www.cgen.com}}
| footnotes        = <ref>{{cite web|title=CGEN Income Statement|url=http://finance.yahoo.com/q/is?s=CGEN+Income+Statement&annual|work=[[Yahoo! Finance]]|accessdate=13 December 2011|year=2011}}</ref>
| intl             =
}}
'''Compugen''' ({{Lang-he|קומפיוג'ן}}) is a publicly traded [[drug discovery]] company headquartered in [[Israel]], with shares traded on the [[NASDAQ Capital Market]] and on the [[Tel Aviv Stock Exchange]].

== Operations ==
Compugen operates in two areas of the biotechnology industry: it develops and markets [[bioinformatics]] software platforms and engages in ''in silico'' drug discovery.<ref name=commander>{{cite book|last=Khavul|first=Susanna|title=The Software Industry in Emerging Markets|year=2005|publisher=[[Edward Elgar Publishing]]|location=[[Gloucestershire, United Kingdom]]|isbn=1-84542-247-3|pages=174–175|url=http://books.google.co.il/books?id=hrfj3hXH76QC|editor=Simon Commander|accessdate=13 December 2011|chapter=Chapter 4: Israel}}</ref> Over the years it has partnered with companies the likes of [[Pfizer]], [[Novartis]], [[Abbott Laboratories|Abbott]], [[BioLineRx]], and Seattle Genetics.<ref>{{cite news|last=Marcial|first=Gene G.|title=Promising Leads at Compugen|url=http://www.businessweek.com/magazine/content/01_37/b3748138.htm|accessdate=13 December 2011|newspaper=[[Bloomberg Businessweek]]|date=10 September 2001}}</ref><ref>{{cite book|first1=Nick|last1=Davies|first2=Heather|last2=Ahlborn|first3=Stuart|last3=Henderson|title=Computer Applications in Pharmaceutical Research and Development|year=2006|publisher=[[Wiley Interscience]]|location=[[Hoboken, New Jersey]]|isbn=978-0-471-73779-7|url=http://books.google.co.il/books?id=mrbIcHtzbL0C|editor=[[Sean Ekins]]|accessdate=13 December 2011|page=761|chapter=Chapter 32: Powerful, Predictive and Pervasive: The Future of Computers in the Pharmaceutical Industry}}</ref><ref>{{cite news|title=Abbott leases Compugen LEADS drug development platform|url=http://www.haaretz.com/news/abbott-leases-compugen-leads-drug-development-platform-1.22166|accessdate=13 December 2011|newspaper=[[Haaretz]]|date=15 January 2003|agency=[[TheMarker]]}}</ref><ref>{{cite news|title=BioLineRx to Develop and Commercialize Novel Peptide Drug Candidates Discovered by Compugen|url=http://finance.yahoo.com/news/biolinerx-develop-commercialize-novel-peptide-110000593.html|accessdate=13 December 2011|newspaper=[[Yahoo! Finance]]|date=13 December 2011|agency=[[Business Wire]]|location=Jerusalem and Tel Aviv, Israel}}</ref><ref>{{cite news|title=Seattle Genetics, Compugen sign cancer drug deal|url=http://seattletimes.nwsource.com/html/businesstechnology/2013291989_sgen30.html|accessdate=13 December 2011|newspaper=[[The Seattle Times]]|date=29 October 2010|agency=[[Associated Press]]}}</ref> [[Amgen]] and [[Bayer]] are among Compugen's competitors.<ref>{{cite web|title=Compugen Ltd: Company profile from Hoover's|url=http://www.hoovers.com/company/Compugen_Ltd/rftfyxi-1.html|publisher=[[Hoover's]]|accessdate=13 December 2011|year=2011}}</ref>

== History ==
Compugen was founded in 1993 by Eli Mintz, Simchon Faigler and Amir Natan. Mintz conceived of the idea for the company in 1991 while accompanying his wife, Liat Mintz, to a [[genomics]] engagement at the [[Pasteur Institute]] in France. She commented that the quantities of data being produced by scientists involved in [[DNA sequencing]] exceeded what computers could process at reasonable speeds. Eli Mintz partnered with colleagues Faigler and Natan from the [[Israel Defense Forces|IDF]]'s elite [[Talpiot program]] to develop a more powerful computer; and indeed, the company's first computer, dubbed the "Bioccelerator," boasted speeds up to one thousand times faster than other platforms being used at the time.<ref name=commander /><ref>{{cite web|last=Blackburn|first=Nicky|title=Computing the benefits of genes and proteins|url=http://www.israel21c.org/health/computing-the-benefits-of-genes-and-proteins|work=Israel21c|accessdate=13 December 2011|date=12 November 2001}}</ref><ref>{{cite news|last=Ginzburg|first=Ami|title=תהליך האבולוציה של קומפיוג'ן|url=http://www.haaretz.co.il/misc/1.723162|accessdate=13 December 2011|newspaper=[[Haaretz]]|date=3 August 2001|language=Hebrew|trans_title=Compugen's evolution|quote=מערכת המחשב שפותחה היתה מסוגלת לבצע השוואות של רצפים גנטיים במהירות של עד פי 1,000 ממערכות אחרות.}}</ref> In 1997, the company followed this success by introducing LEADS, an [[Expressed sequence tag|EST]] clustering and assembly platform.<ref>{{cite web|last=Russell|first=John|title=Compugen Transforms Its Business|url=http://www.bio-itworld.com/issues/2005/oct/bus-compugen/|publisher=Bio-ITWorld.com|accessdate=13 December 2011|date=17 October 2005}}</ref><ref>{{cite book|first1=Hanqing|last1=Xie|first2=Raveh|last2=Gill-More|editor1-last=Seckbach|editor1-first=Joseph|editor2-last=Rubin|editor2-first=Eitan|title=The New Avenues in Bioinformatics|year=2004|publisher=[[Kluwer Academic Publishers]]|location=[[Dordrecht]]|isbn=1-4020-2639-0|url=http://books.google.co.il/books?id=X__9-t4M37IC|accessdate=13 December 2011|page=153|chapter=Transcriptome Analysis Through Expressed Sequences}}</ref> By around 2001, Compugen had effected a shift in its business model from a company whose almost exclusive focus was marketing computer programs and applications to one whose operations extended into the diagnostics and therapeutics fields.<ref>{{cite news|last=Pincas|first=Gitit|title=Compugen's metamorphosis|url=http://www.globes.co.il/serveen/globes/docview.asp?did=849904|accessdate=15 December 2011|newspaper=[[Globes]]|date=1 November 2004}}</ref><ref>{{cite news|last=Coren|first=Ora|title=קומפיוג'ן עוברת לפיתוח תרופות|url=http://www.themarker.com/hitech/1.72173|accessdate=13 December 2011|newspaper=[[TheMarker]]|date=4 May 2001|language=Hebrew|trans_title=Compugen transitions to development of drugs|quote=לדבריו, החברה מעוניינת לזהות את ההזדמנויות ולהיות שותפה בתחומי הדיאגנוסטיקה והתרפויטיקה, לא רק למכור תוכנות ואפליקציות.}}</ref>

Compugen began trading on the Nasdaq in 2000 and on the Tel Aviv Stock Exchange in 2002.<ref>{{cite web|title=Compugen Company Profile|url=http://www.bioportfolio.com/corporate/company/17835/Compugen.html|publisher=BioPortfolio|accessdate=13 December 2011}}</ref> Also in 2002, Compugen [[Corporate spin-off|spun off]] its subsidiary [[Evogene]], established as an [[agriscience]] division in 1999.<ref>{{cite news|last=Coren|first=Ora|title=Propagating the Evogene way|url=http://www.haaretz.com/print-edition/business/propagating-the-evogene-way-1.114297|accessdate=13 December 2011|newspaper=[[Haaretz]]|date=18 February 2004}}</ref><ref>{{cite news|title=Evogene, a Subsidiary of Compugen, Raising U.S. $2.0 Million in Private Financing|url=http://www.allbusiness.com/company-activities-management/company-structures-ownership/5669137-1.html|accessdate=13 December 2011|newspaper=[[AllBusiness.com]]|date=6 January 2003|agency=[[Business Wire]]|location=[[Tel Aviv, Israel]]}}</ref>

=== Management ===
Mor Amitai, [[Hebrew University]] alumnus (Ph.D, Mathematics), who joined Compugen in 1994, was the company's CEO and president from 1998 to 2005. He was replaced by Alex Kotzer, [[Technion]] alumnus ([[Chemical Engineering]]), who was CEO and president through 2008.<ref>{{cite news|last=Tsipori|first=Tali|title=Compugen to Raise $55 Mln at $280 Mln Value Tonight|url=http://www.globes.co.il/serveen/globes/docview.asp?did=387406|accessdate=15 December 2011|newspaper=[[Globes]]|date=13 August 2000}}</ref><ref>{{cite web|title=Compugen Ltd (CGEN) – 6-K – 7/2/2003|url=http://google.brand.edgar-online.com/DisplayFilingInfo.aspx?Type=HTML&text=%2526lt%253bNEAR%252f4%2526gt%253b%28%22DALIA%22%2C%22COHEN%22%29&FilingID=2370361&ppu=%2FPeopleFilingResults.aspx%3FPersonID%3D3368849|publisher=[[EDGAR Online]]|accessdate=15 December 2011|date=2 June 2003}}</ref><ref>{{cite web|title=Compugen Ltd – 6-K – 20080820 - Form|url=http://google.brand.edgar-online.com/EFX_dll/EDGARpro.dll?FetchFilingHtmlSection1?SectionID=6113666-749-27094&SessionID=0u5qHWvshMMRQ17|publisher=[[EDGAR Online]]|accessdate=15 December 2011|year=2008}}</ref><ref>{{cite web|title=Alex Kotzer Profile|url=http://people.forbes.com/profile/alex-kotzer/22221|publisher=[[Forbes.com]]|accessdate=15 December 2011}}</ref> [[Anat Cohen-Dayag]], [[Weizmann Institute]] alumnus (Ph.D, [[Cellular Biology]]), became co-CEO of Compugen in 2009, serving alongside [[Martin Gerstel]], [[Yale]] alumnus (Engineering). She has been the company's exclusive CEO since 2010.<ref>{{cite news|title=Anat Cohen Dayag Profile – Forbes.com|url=http://people.forbes.com/profile/anat-cohen-dayag/22235|accessdate=13 December 2011|newspaper=[[Forbes]]}}</ref><ref>{{cite web|last=London Sappir|first=Shoshana|title=Martin Gerstel's back in business, this time in Israel|url=http://www.israel21c.org/technology/martin-gerstel-s-back-in-business-this-time-in-israel|publisher=Israel21c|accessdate=13 December 2011|date=4 March 2002}}</ref>

== See also ==
* [[Human Genome Project]]
* [[In silico]]
* [[Transcriptome]]
* [[Genesis Partners]]
* [[List of Israeli companies quoted on the Nasdaq]]

== References ==
{{Reflist|2}}

== Further reading ==
* {{cite journal|date=25 February 2010|title=Compugen hits gold with Pfizer|journal=Biopharmaceutiques|issue=126|url=http://www.biopharmaceutiques.com/en/article/126_2133.html|publisher=PR Editions|location=[[France]]}}
* {{cite news|last=Pitta|first=Julie|title=E=mc$$|url=http://www.forbes.com/forbes/1998/0223/6104116a.html|newspaper=[[Forbes]]|date=23 February 1998}}
* {{cite journal|last=Rosenberg|first=David|title=Israeli Army Grads Lead Business Revolution|journal=[[Red Herring (magazine){{!}}Red Herring]]|year=2000|month=September|url=http://www.cji.co.il/cji-n126.txt}}
* {{cite web|title=President & CEO of Compugen Ltd. talks about potential long-term large revenues from licensing of in-house discoveries|url=http://www.twst.com/notes/articles/lxs082.html|publisher=[[The Wall Street Transcript]]|date=30 April 2003}}

== External links ==
{{Finance links
| name = Compugen
| symbol = CGEN
| sec_cik = 1119774
}}

{{Israel NASDAQ}}

[[Category:Companies listed on TASE]]
[[Category:Biotechnology companies of Israel]]
[[Category:Companies established in 1993]]
[[Category:Companies listed on NASDAQ]]
[[Category:Drug discovery companies]]